UCB1577571

UCB1577571 is a preclinical-stage dual inhibitor targeting both interleukin-17A (IL-17A) and interleukin-17F (IL-17F). Developed by UCB, it is designed to treat inflammatory conditions such as psoriasis by neutralizing the pro-inflammatory cytokines IL-17A and IL-17F, which play a central role in the pathogenesis of plaque psoriasis. Unlike bimekizumab, which is a full monoclonal antibody, UCB1577571 is characterized in research as a bispecific nanobody or antibody fragment. Preclinical studies, including those utilizing the Derphartox human psoriasis skin transplant model, have demonstrated its ability to reduce epidermal thickness and inflammatory cell infiltration in grafted psoriatic skin.